Home > Financial Ratios > GLAND PHARMA

GLAND PHARMA
Core EBITDA Growth

    Back to All Ratios
GLAND PHARMA is part of below Screeners ↓
Top Mid Cap Stocks with Best Fundamentals
Best 1M Momentum Mid Cap Stocks
COMMUNITY POLL
for GLAND PHARMA
Please provide your vote to see the results

GLAND PHARMA Last 5 Year Core EBITDA Growth History

[Consolidated]

Mar2026Mar2025Mar2024Mar2023Mar2022
   Core EBITDA Growth(%) 31.25-1.3818.82-27.0420.67

What is the latest Core EBITDA Growth ratio of GLAND PHARMA ?

The latest Core EBITDA Growth ratio of GLAND PHARMA is 31.25 based on Mar2026 Consolidated results.
Year Core EBITDA Growth
Mar202631.25
Mar2025-1.38
Mar202418.82
Mar2023-27.04
Mar202220.67

How is Core EBITDA Growth of GLAND PHARMA Trending?

Years Core EBITDA Growth % Change
Mar2026 31.25
Positive
Mar2025 -1.38
Negative
Mar2024 18.82
Positive
Mar2023 -27.04
Negative
Mar2022 20.67 -

Other Financial Ratios of GLAND PHARMA


Compare Core EBITDA Growth ratio of peers of GLAND PHARMA

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
GLAND PHARMA ₹48,384.6 Cr 1.5% 12% 55.4% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹455,634.0 Cr -2.9% -2.3% 21.8% Stock Analytics
DIVIS LABORATORIES ₹241,576.0 Cr -1.6% 9.8% 51.8% Stock Analytics
TORRENT PHARMACEUTICALS ₹184,478.0 Cr -2.6% -2.3% 37.5% Stock Analytics
CIPLA ₹111,888.0 Cr -2.2% -6.1% -12.5% Stock Analytics
DR REDDYS LABORATORIES ₹96,322.1 Cr -0.9% -1.8% -9.8% Stock Analytics


GLAND PHARMA Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
GLAND PHARMA

1.5%

12%

55.4%

SENSEX

-1%

-2.6%

-4.1%


You may also like the below Video Courses